The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir [3]

British Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 250-252

  Burger, David M ^a   Schwietert, H Reinier ^b   Colbers, E P H ^c   Becker, Mark ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Xendo Drug Development Services   (Netherlands)

^c Farma Research   (Netherlands)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; NELFINAVIR; PROTEINASE INHIBITOR; UNSPECIFIC MONOOXYGENASE;

GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HUMAN; LETTER; MUTATION;

ARYL HYDROCARBON HYDROXYLASES; HETEROZYGOTE; HIV PROTEASE INHIBITORS; HUMANS; MIXED FUNCTION OXYGENASES; MUTATION; NELFINAVIR; POLYMORPHISM, GENETIC;

EID: 33748276973     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02635.x     Document Type: Letter

References (9)

1. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 2004; 32: 1462-7.
2. Lillibridge JH. Lee CA, Pithavala YK, Daniels RG, Samuel TM, Wu EY, Zhang KE, Mazabel EL, Zhang M, Kerr BM. The Role of Polymorphic CYP 2C19 in the Metabolism of Nelfinavir Mesylate. 12th AAPS Conference 1998, abstract 3035.
3. Khaliq Y, Gallicano K, Seguin I, Fyke K, Carignan G, Bulman D, Badley A, Cameron DW. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 2000; 50: 108-15.
4. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
5. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004; 19: 83-95.
6. Droste JAH, Verweij-van Wissen CPWGM, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
7. Burger DM, Hugen PW, Aarnoutse RE, Hoetelmans RM, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, Van Der Ende ME, Lange JM. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25: 73-80.
8. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002; 16: 1331-40.
9. Haas DW, Smeaton L, Shafer R, Robbins G, Morse G, Labbe L, Wilkinson G, Clifford D, Dube M, D'Aquila R, DeGruttola D, Pollard R, George A, Donahue J, Kim R. Pharmacogenetics of Long-Term Response to Efavirenz- and Nelfinavir-Containing Regimens: NWCS213, an Analysis of ACTG384. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. USA. 22-25 February 2005. Abstract 81.